Ricard Corcelles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ricard Corcelles has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Matthew Kroh
Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio
14 shared publications - Jerry T. Dang
Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio
13 shared publications - John Rodriguez
Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
10 shared publications - Valentin Mocanu
Cleveland clinic, Cleveland, United States
10 shared publications - Juan Sebastian Barajas-Gamboa
Digestive Disease Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
9 shared publications - Alfredo Daniel Guerron
Digestive Disease Institute, Department of General Surgery, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
8 shared publications
Latest Publications
- 2 November 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Cirrhosis Regression After Metabolic Bariatric Surgery in Patients With Compensated MASH Cirrhosis
Objective: To evaluate histologic cirrhosis regression after metabolic bariatric surgery (MBS) in patients with compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis. Summary Background Data: Cirrhosis in MASH has traditionally been considered irreversible. Although MBS improves steatohepatitis and fibrosis in noncirrhotic MASH, its impact on established cirrhosis remains uncertain. Methods: This retrospective study included adults with biopsy-proven compensated MASH cirrhosis who underwent MBS at Cleveland Clinic from 2004 to 2024 and had paired baseline and follow-up liver biopsies. The primary outcome was regression from NASH Clinical Research Network (NASH CRN) stage 4 to stage 3 or lower. Fibrosis was also assessed using modified Ishak staging and the Beijing classification. Results: Thirty patients were included; 22 (73%) were female, median age was 54.2 years, and median baseline body mass index was 43.7 kg/m². The median (IQR) biopsy interval was 6.2 (2.0–9.2) years, median body weight reduction was 31.8 (21.4–40.4) kg, and median total weight loss was 23.9% (18.0%–30.5%). Cirrhosis regression occurred in 33% of patients using NASH CRN staging and in 40% using modified Ishak staging. Regressive fibrosis features were identified in 60% of patients using the Beijing classification. Significant improvements were also observed in steatosis, lobular inflammation, and hepatocyte ballooning. Conclusions: MBS was associated with histologic cirrhosis regression in a substantial proportion of patients with biopsy-proven compensated MASH cirrhosis. More detailed histologic frameworks identified additional fibrosis improvement and regressive remodeling, suggesting that compensated MASH cirrhosis may be reversible after sustained metabolic intervention.
- 2 November 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Cirrhosis Regression After Metabolic Bariatric Surgery in Patients With Compensated MASH Cirrhosis
Objective: To evaluate histologic cirrhosis regression after metabolic bariatric surgery (MBS) in patients with compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis. Summary Background Data: Cirrhosis in MASH has traditionally been considered irreversible. Although MBS improves steatohepatitis and fibrosis in noncirrhotic MASH, its impact on established cirrhosis remains uncertain. Methods: This retrospective study included adults with biopsy-proven compensated MASH cirrhosis who underwent MBS at Cleveland Clinic from 2004 to 2024 and had paired baseline and follow-up liver biopsies. The primary outcome was regression from NASH Clinical Research Network (NASH CRN) stage 4 to stage 3 or lower. Fibrosis was also assessed using modified Ishak staging and the Beijing classification. Results: Thirty patients were included; 22 (73%) were female, median age was 54.2 years, and median baseline body mass index was 43.7 kg/m². The median (IQR) biopsy interval was 6.2 (2.0–9.2) years, median body weight reduction was 31.8 (21.4–40.4) kg, and median total weight loss was 23.9% (18.0%–30.5%). Cirrhosis regression occurred in 33% of patients using NASH CRN staging and in 40% using modified Ishak staging. Regressive fibrosis features were identified in 60% of patients using the Beijing classification. Significant improvements were also observed in steatosis, lobular inflammation, and hepatocyte ballooning. Conclusions: MBS was associated with histologic cirrhosis regression in a substantial proportion of patients with biopsy-proven compensated MASH cirrhosis. More detailed histologic frameworks identified additional fibrosis improvement and regressive remodeling, suggesting that compensated MASH cirrhosis may be reversible after sustained metabolic intervention.
- Open Access
- 9 January 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (3) , 1125-1134
Heart Failure Independently Predicts Higher Morbidity and Mortality Following Bariatric Surgery: Analysis of 180,544 MBSAQIP Cases
Introduction: Heart failure (HF) and obesity represent intersecting public health epidemics with significant healthcare implications. As obesity-related heart failure becomes increasingly prevalent, understanding the perioperative risks and outcomes of bariatric surgery in this vulnerable population is essential. This study aimed to analyze procedure-specific outcomes and cardiac complications in heart failure patients undergoing primary bariatric surgery using a large multi-institutional database. Methods and Procedures: We conducted a retrospective analysis using the 2023 MBSAQIP database, examining adult patients who underwent primary laparoscopic bariatric procedures (sleeve gastrectomy or Roux-en-Y gastric bypass). Patients were stratified into heart failure and non-heart failure cohorts. The primary outcomes evaluated were 30-day serious complications and mortality. Multivariable logistic regression analyses were performed to identify independent predictors of complications and mortality, adjusting for demographics, comorbidities, and operative factors. Results: Among 180,544 patients, 2,842 (1.6%) had pre-existing heart failure documented preoperatively. HF patients were significantly older (53.3 ± 11.0 vs. 42.8 ± 11.8 years, p < 0.001) with higher BMI (48.6 ± 9.5 vs. 45.0 ± 7.7 kg/m², p < 0.001) and greater comorbidity burden. Procedure distribution was similar between groups (SG: 70.7% vs. 72.1%, RYGB: 29.3% vs. 27.9%, p = 0.091). HF patients experienced significantly higher rates of serious complications (7.2% vs. 2.4%, p < 0.001) and mortality (0.74% vs. 0.06%, p < 0.001). Cardiac events occurred 13 times more frequently in HF patients (1.3% vs. 0.1%, p < 0.001). Hospital length of stay was longer (1.9 ± 2.9 vs. 1.2 ± 1.0 days, p < 0.001), with higher readmission rates (7.8% vs. 2.8%, p < 0.001). On multivariable analysis, pre-existing HF was the strongest independent predictor of serious complications (OR 1.81; 95% CI 1.55–2.13; p < 0.001) and a powerful predictor of 30-day mortality (OR 3.64; 95% CI 2.14–6.20; p < 0.001). Conclusion: Heart failure is a major independent predictor of both serious complications and mortality following bariatric surgery, occurring in nearly 2% of all elective cases. Despite the established long-term benefits of bariatric surgery for HF patients, the substantially elevated perioperative risks require careful patient selection, thorough preoperative cardiac assessment, and specialized perioperative management strategies to optimize outcomes in this high-risk population.
- 9 January 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (3) , 1125-1134
Open AccessHeart Failure Independently Predicts Higher Morbidity and Mortality Following Bariatric Surgery: Analysis of 180,544 MBSAQIP Cases
Introduction: Heart failure (HF) and obesity represent intersecting public health epidemics with significant healthcare implications. As obesity-related heart failure becomes increasingly prevalent, understanding the perioperative risks and outcomes of bariatric surgery in this vulnerable population is essential. This study aimed to analyze procedure-specific outcomes and cardiac complications in heart failure patients undergoing primary bariatric surgery using a large multi-institutional database. Methods and Procedures: We conducted a retrospective analysis using the 2023 MBSAQIP database, examining adult patients who underwent primary laparoscopic bariatric procedures (sleeve gastrectomy or Roux-en-Y gastric bypass). Patients were stratified into heart failure and non-heart failure cohorts. The primary outcomes evaluated were 30-day serious complications and mortality. Multivariable logistic regression analyses were performed to identify independent predictors of complications and mortality, adjusting for demographics, comorbidities, and operative factors. Results: Among 180,544 patients, 2,842 (1.6%) had pre-existing heart failure documented preoperatively. HF patients were significantly older (53.3 ± 11.0 vs. 42.8 ± 11.8 years, p < 0.001) with higher BMI (48.6 ± 9.5 vs. 45.0 ± 7.7 kg/m², p < 0.001) and greater comorbidity burden. Procedure distribution was similar between groups (SG: 70.7% vs. 72.1%, RYGB: 29.3% vs. 27.9%, p = 0.091). HF patients experienced significantly higher rates of serious complications (7.2% vs. 2.4%, p < 0.001) and mortality (0.74% vs. 0.06%, p < 0.001). Cardiac events occurred 13 times more frequently in HF patients (1.3% vs. 0.1%, p < 0.001). Hospital length of stay was longer (1.9 ± 2.9 vs. 1.2 ± 1.0 days, p < 0.001), with higher readmission rates (7.8% vs. 2.8%, p < 0.001). On multivariable analysis, pre-existing HF was the strongest independent predictor of serious complications (OR 1.81; 95% CI 1.55–2.13; p < 0.001) and a powerful predictor of 30-day mortality (OR 3.64; 95% CI 2.14–6.20; p < 0.001). Conclusion: Heart failure is a major independent predictor of both serious complications and mortality following bariatric surgery, occurring in nearly 2% of all elective cases. Despite the established long-term benefits of bariatric surgery for HF patients, the substantially elevated perioperative risks require careful patient selection, thorough preoperative cardiac assessment, and specialized perioperative management strategies to optimize outcomes in this high-risk population.
- 11 December 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (2) , 429-438
Robotic RYGB is Associated with Increased Risk of Early Postoperative Small Bowel Obstruction: an Analysis of 188,213 MBSAQIP Cases
Introduction Small bowel obstruction (SBO) represents a serious early complication following Roux-en-Y gastric bypass (RYGB) surgery. With the widespread adoption of robotic platforms in bariatric surgery, understanding the impact of robotic assistance on postoperative complications has become increasingly important. However, the association between robotic assistance and early SBO risk remains unclear in the current literature. This study aimed to evaluate the relationship between robotic assistance and early postoperative small bowel obstruction following primary RYGB procedures. Methods and Procedures We conducted a retrospective cohort study analyzing the 2020–2023 Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database from over 900 accredited bariatric surgery centers across the United States and Canada. Patients undergoing primary RYGB were stratified by occurrence of 30-day SBO. The primary outcomes evaluated were early postoperative small bowel obstruction rates, reoperation rates, and readmission rates. Multivariable logistic regression was used to identify independent predictors of SBO, adjusting for patient demographics, comorbidities, and operative factors. Results A total of 188,213 RYGB procedures were included in the study, with 1,704 patients (0.9%) developing early SBO. Robotic assistance was utilized in 29.2% of cases. Baseline characteristics showed that SBO patients were predominantly female (90.1% vs. 83.4%, p < 0.001) with lower BMI (43.6 vs. 45.5 kg/m², p < 0.001) and longer operative times (141.7 vs. 124.7 min, p < 0.001). SBO occurred more frequently with robotic assistance compared to conventional approaches (1.2% vs. 0.8%, p < 0.001), representing an absolute risk difference of 0.4% or approximately 4 additional SBO cases per 1,000 robotic procedures. Multivariable analysis confirmed robotic assistance as an independent risk factor for early SBO (OR 1.30, 95% CI 1.17–1.44, p < 0.001), alongside female sex (OR 1.76) and VTE history (OR 1.55). SBO cases showed significantly higher reoperation rates (54.7% vs. 1.2%) and readmission rates (75.1% vs. 4.1%) compared to patients without SBO. Conclusion Robotic assistance is independently associated with increased early SBO risk following RYGB (OR 1.30, absolute risk 1.2% vs. 0.8%, 4 additional cases per 1,000 procedures). While the absolute risk increase is modest, these findings necessitate balanced patient counseling that incorporates both this increased early SBO risk and potential benefits of robotic approaches. These results support the development of standardized robotic protocols to mitigate SBO occurrence while leveraging the advantages of robotic technology in bariatric surgery centers.
- 11 December 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (2) , 429-438
Robotic RYGB is Associated with Increased Risk of Early Postoperative Small Bowel Obstruction: an Analysis of 188,213 MBSAQIP Cases
Introduction Small bowel obstruction (SBO) represents a serious early complication following Roux-en-Y gastric bypass (RYGB) surgery. With the widespread adoption of robotic platforms in bariatric surgery, understanding the impact of robotic assistance on postoperative complications has become increasingly important. However, the association between robotic assistance and early SBO risk remains unclear in the current literature. This study aimed to evaluate the relationship between robotic assistance and early postoperative small bowel obstruction following primary RYGB procedures. Methods and Procedures We conducted a retrospective cohort study analyzing the 2020–2023 Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database from over 900 accredited bariatric surgery centers across the United States and Canada. Patients undergoing primary RYGB were stratified by occurrence of 30-day SBO. The primary outcomes evaluated were early postoperative small bowel obstruction rates, reoperation rates, and readmission rates. Multivariable logistic regression was used to identify independent predictors of SBO, adjusting for patient demographics, comorbidities, and operative factors. Results A total of 188,213 RYGB procedures were included in the study, with 1,704 patients (0.9%) developing early SBO. Robotic assistance was utilized in 29.2% of cases. Baseline characteristics showed that SBO patients were predominantly female (90.1% vs. 83.4%, p < 0.001) with lower BMI (43.6 vs. 45.5 kg/m², p < 0.001) and longer operative times (141.7 vs. 124.7 min, p < 0.001). SBO occurred more frequently with robotic assistance compared to conventional approaches (1.2% vs. 0.8%, p < 0.001), representing an absolute risk difference of 0.4% or approximately 4 additional SBO cases per 1,000 robotic procedures. Multivariable analysis confirmed robotic assistance as an independent risk factor for early SBO (OR 1.30, 95% CI 1.17–1.44, p < 0.001), alongside female sex (OR 1.76) and VTE history (OR 1.55). SBO cases showed significantly higher reoperation rates (54.7% vs. 1.2%) and readmission rates (75.1% vs. 4.1%) compared to patients without SBO. Conclusion Robotic assistance is independently associated with increased early SBO risk following RYGB (OR 1.30, absolute risk 1.2% vs. 0.8%, 4 additional cases per 1,000 procedures). While the absolute risk increase is modest, these findings necessitate balanced patient counseling that incorporates both this increased early SBO risk and potential benefits of robotic approaches. These results support the development of standardized robotic protocols to mitigate SBO occurrence while leveraging the advantages of robotic technology in bariatric surgery centers.
- Open Access
- 22 November 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (1) , 20-28
Roux-en-Y Gastric Bypass and Sleeve Gastrectomy Risk-Adjusted Safety Profiles after Previous Fundoplication: A 499-Patient MBSAQIP Analysis
Background: Obesity and gastroesophageal reflux disease (GERD) frequently coexist and may necessitate surgical intervention when conservative management fails. While fundoplication is effective for GERD, many patients ultimately require metabolic and bariatric surgery (MBS) for obesity. The safety and prevalence of sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) after prior fundoplication remains poorly characterized. Objectives: To assess the prevalence and 30-day serious complication rates of SG and RYGB following fundoplication, and to identify independent predictors of adverse outcomes. Methods: A retrospective analysis of the 2022–2023 MBSAQIP database identified 499 patients undergoing primary SG or RYGB after fundoplication. Outcomes assessed included leak, bleeding, reoperation, reintervention, cardiac events, pneumonia, kidney injury, thromboembolism, infection, or sepsis. Multivariable logistic regression was used to adjust for baseline differences. Results: Of 499 patients, 126 (25.3%) underwent SG (F-SG) and 373 (74.7%) underwent RYGB (F-RYGB). Concomitant paraesophageal hernia repair was more common in the F-RYGB group (54.2% vs. 26.2%, p < 0.001). Mean BMI was higher in F-SG (42.4 vs. 40.1 kg/m², p < 0.001). Weight gain and GERD were the leading indications for revisional bariatric surgery. F-RYGB was associated with longer operative times, hospital stay, and higher rates of reoperation, readmission, bowel obstruction, and serious complications (9.6% vs. 4.0%, p = 0.045). Rates of anastomotic leak, postoperative bleeding, and composite wound complications were low but numerically higher in F-RYGB, without statistical significance. In multivariate analysis, procedure type was not significantly associated with serious complications (OR 2.03, 95% CI 0.68–6.09, p = 0.207). Conclusions: Both SG and RYGB appear to be safe and effective revisional options, and a history of fundoplication should not be considered a contraindication. Although RYGB was associated with longer operative times and higher early complication rates, multivariable analysis showed no significant difference in serious complications between the two procedures.
- 22 November 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (1) , 20-28
Open AccessRoux-en-Y Gastric Bypass and Sleeve Gastrectomy Risk-Adjusted Safety Profiles after Previous Fundoplication: A 499-Patient MBSAQIP Analysis
Background: Obesity and gastroesophageal reflux disease (GERD) frequently coexist and may necessitate surgical intervention when conservative management fails. While fundoplication is effective for GERD, many patients ultimately require metabolic and bariatric surgery (MBS) for obesity. The safety and prevalence of sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) after prior fundoplication remains poorly characterized. Objectives: To assess the prevalence and 30-day serious complication rates of SG and RYGB following fundoplication, and to identify independent predictors of adverse outcomes. Methods: A retrospective analysis of the 2022–2023 MBSAQIP database identified 499 patients undergoing primary SG or RYGB after fundoplication. Outcomes assessed included leak, bleeding, reoperation, reintervention, cardiac events, pneumonia, kidney injury, thromboembolism, infection, or sepsis. Multivariable logistic regression was used to adjust for baseline differences. Results: Of 499 patients, 126 (25.3%) underwent SG (F-SG) and 373 (74.7%) underwent RYGB (F-RYGB). Concomitant paraesophageal hernia repair was more common in the F-RYGB group (54.2% vs. 26.2%, p < 0.001). Mean BMI was higher in F-SG (42.4 vs. 40.1 kg/m², p < 0.001). Weight gain and GERD were the leading indications for revisional bariatric surgery. F-RYGB was associated with longer operative times, hospital stay, and higher rates of reoperation, readmission, bowel obstruction, and serious complications (9.6% vs. 4.0%, p = 0.045). Rates of anastomotic leak, postoperative bleeding, and composite wound complications were low but numerically higher in F-RYGB, without statistical significance. In multivariate analysis, procedure type was not significantly associated with serious complications (OR 2.03, 95% CI 0.68–6.09, p = 0.207). Conclusions: Both SG and RYGB appear to be safe and effective revisional options, and a history of fundoplication should not be considered a contraindication. Although RYGB was associated with longer operative times and higher early complication rates, multivariable analysis showed no significant difference in serious complications between the two procedures.
- Open Access
- 25 September 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (11) , 4752-4765
Concomitant Liver Biopsy During Bariatric Surgery: No Increase in Major Complications or Readmissions but Associated with Higher Transfusion Requirements - An Analysis of the MBSAQIP Database
Introduction: Concomitant liver biopsy during bariatric surgery has gained interest for diagnostic and research purposes, particularly in studying obesity-related liver disease. However, comprehensive data on safety remains limited using recent national databases. Methods: A retrospective analysis of the MBSAQIP database from 2020 to 2022 was conducted. Patients undergoing primary Roux-en-Y gastric bypass or sleeve gastrectomy with or without concomitant liver biopsy were included. Primary outcomes were 30-day major complications (Clavien-Dindo grade III and IV) and mortality. Separate multivariable analyses were performed for bleeding-related complications including postoperative bleeding, transfusion requirements, and reoperation. Multivariable logistic regression analysis determined if concomitant liver biopsy independently predicted adverse outcomes. Results: Of 511,981 patients, 30,819 (6.02%) underwent concomitant liver biopsy. Biopsy patients had higher rates of diabetes (28.25% vs 22.65%, p < 0.001) and hyperlipidemia (25.20% vs 22.14%, p < 0.001). Mean operative time was longer in the biopsy group (96.10 vs 83.59 min, p < 0.001). Unadjusted analysis showed higher rates of major complications (Clavien-Dindo grade III and IV) (3.15% vs 2.70%, p < 0.001) and 30-day readmission (3.32% vs 2.86%, p < 0.001) in the biopsy group. However, on multivariable analysis, concomitant liver biopsy was not independently predictive of major complications (OR 0.91, 95%CI 0.79–1.04, p = 0.164) or 30-day readmission (OR 1.06, 95%CI 0.94–1.21, p = 0.344). Separate multivariable analyses for bleeding-related complications revealed that concomitant liver biopsy was independently associated with increased postoperative bleeding (OR 1.203, 95%CI 1.018–1.422, p = 0.030) and transfusion requirements (OR 1.171, 95%CI 1.028–1.334, p = 0.018), but not with reoperation (OR 1.016, 95%CI 0.908–1.138, p = 0.783). Conclusion: After adjusting for patient factors, concomitant liver biopsy during bariatric surgery does not independently increase the risk of major complications (Clavien-Dindo grade III and IV), readmission, or mortality. However, it is associated with increased bleeding and transfusion complications. These findings support that liver biopsy can be performed during bariatric surgery, though clinicians should be prepared for increased bleeding-related risks and blood product utilization.
- 25 September 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (11) , 4752-4765
Open AccessConcomitant Liver Biopsy During Bariatric Surgery: No Increase in Major Complications or Readmissions but Associated with Higher Transfusion Requirements - An Analysis of the MBSAQIP Database
Introduction: Concomitant liver biopsy during bariatric surgery has gained interest for diagnostic and research purposes, particularly in studying obesity-related liver disease. However, comprehensive data on safety remains limited using recent national databases. Methods: A retrospective analysis of the MBSAQIP database from 2020 to 2022 was conducted. Patients undergoing primary Roux-en-Y gastric bypass or sleeve gastrectomy with or without concomitant liver biopsy were included. Primary outcomes were 30-day major complications (Clavien-Dindo grade III and IV) and mortality. Separate multivariable analyses were performed for bleeding-related complications including postoperative bleeding, transfusion requirements, and reoperation. Multivariable logistic regression analysis determined if concomitant liver biopsy independently predicted adverse outcomes. Results: Of 511,981 patients, 30,819 (6.02%) underwent concomitant liver biopsy. Biopsy patients had higher rates of diabetes (28.25% vs 22.65%, p < 0.001) and hyperlipidemia (25.20% vs 22.14%, p < 0.001). Mean operative time was longer in the biopsy group (96.10 vs 83.59 min, p < 0.001). Unadjusted analysis showed higher rates of major complications (Clavien-Dindo grade III and IV) (3.15% vs 2.70%, p < 0.001) and 30-day readmission (3.32% vs 2.86%, p < 0.001) in the biopsy group. However, on multivariable analysis, concomitant liver biopsy was not independently predictive of major complications (OR 0.91, 95%CI 0.79–1.04, p = 0.164) or 30-day readmission (OR 1.06, 95%CI 0.94–1.21, p = 0.344). Separate multivariable analyses for bleeding-related complications revealed that concomitant liver biopsy was independently associated with increased postoperative bleeding (OR 1.203, 95%CI 1.018–1.422, p = 0.030) and transfusion requirements (OR 1.171, 95%CI 1.028–1.334, p = 0.018), but not with reoperation (OR 1.016, 95%CI 0.908–1.138, p = 0.783). Conclusion: After adjusting for patient factors, concomitant liver biopsy during bariatric surgery does not independently increase the risk of major complications (Clavien-Dindo grade III and IV), readmission, or mortality. However, it is associated with increased bleeding and transfusion complications. These findings support that liver biopsy can be performed during bariatric surgery, though clinicians should be prepared for increased bleeding-related risks and blood product utilization.
- Open Access
- 25 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5262
Counting Limb Length Ratios in Roux-en-Y Gastric Bypass: A Demonstration of Safety and Feasibility Using a 25-Patient Case Series in a High-Volume Academic Center
Background: Despite being one of the most performed bariatric procedures, there is no consensus regarding optimal limb lengths for Roux-en-Y gastric bypass (RYGB), which may impact weight loss and obesity-related comorbidity resolution. We hypothesize that a ratio-adjusted small bowel to Roux and BP limb lengths in RYGB results in superior outcomes. Objectives: This study aims to define total intestinal length (TIL) and the feasibility of its intraoperative measurement during RYGB. The findings will serve as a foundation for a subsequent randomized trial evaluating different limb length ratios and their effect on postoperative outcomes. Setting: This was a single-center prospective cohort study conducted at Cleveland Clinic Foundation-Main Campus, a tertiary referral center in the United States. Methods: Between January and June 2023, 25 patients with BMI > 40 undergoing RYGB were enrolled. Total small bowel length was measured intraoperatively, and feasibility of measurement was assessed. Patient outcomes, including total weight loss, 30-day complications, and comorbidities at 1 year were captured. Results: Mean preoperative BMI was 47.6 ± 8.0 kg/m2. Mean total small bowel length was 592 ± 93.3 cm, with a mean biliopancreatic (BP) limb length of 109 ± 29 cm (18.86% ± 5.84 of total length) and Roux limb length of 103 ± 15 cm (17.71% ± 3.06 of total length). Measurement added an average of 11.5 min to operative time. Measurement feasibility was rated as “moderate” or easier in 80% of cases. One-year postoperative outcomes included a mean total weight loss of 31% and significant reductions in antihypertensive and anti-diabetic medication use. Conclusions: Total small bowel length measurement during RYGB is safe and feasible. High variability in bowel length was observed, with no significant correlation to demographic factors. Establishing individualized limb length ratios may improve weight loss outcomes and comorbidity resolution. Further studies are warranted to evaluate the impact of tailored limb length strategies.
- 25 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5262
Open AccessCounting Limb Length Ratios in Roux-en-Y Gastric Bypass: A Demonstration of Safety and Feasibility Using a 25-Patient Case Series in a High-Volume Academic Center
Background: Despite being one of the most performed bariatric procedures, there is no consensus regarding optimal limb lengths for Roux-en-Y gastric bypass (RYGB), which may impact weight loss and obesity-related comorbidity resolution. We hypothesize that a ratio-adjusted small bowel to Roux and BP limb lengths in RYGB results in superior outcomes. Objectives: This study aims to define total intestinal length (TIL) and the feasibility of its intraoperative measurement during RYGB. The findings will serve as a foundation for a subsequent randomized trial evaluating different limb length ratios and their effect on postoperative outcomes. Setting: This was a single-center prospective cohort study conducted at Cleveland Clinic Foundation-Main Campus, a tertiary referral center in the United States. Methods: Between January and June 2023, 25 patients with BMI > 40 undergoing RYGB were enrolled. Total small bowel length was measured intraoperatively, and feasibility of measurement was assessed. Patient outcomes, including total weight loss, 30-day complications, and comorbidities at 1 year were captured. Results: Mean preoperative BMI was 47.6 ± 8.0 kg/m2. Mean total small bowel length was 592 ± 93.3 cm, with a mean biliopancreatic (BP) limb length of 109 ± 29 cm (18.86% ± 5.84 of total length) and Roux limb length of 103 ± 15 cm (17.71% ± 3.06 of total length). Measurement added an average of 11.5 min to operative time. Measurement feasibility was rated as “moderate” or easier in 80% of cases. One-year postoperative outcomes included a mean total weight loss of 31% and significant reductions in antihypertensive and anti-diabetic medication use. Conclusions: Total small bowel length measurement during RYGB is safe and feasible. High variability in bowel length was observed, with no significant correlation to demographic factors. Establishing individualized limb length ratios may improve weight loss outcomes and comorbidity resolution. Further studies are warranted to evaluate the impact of tailored limb length strategies.
- Open Access
- 5 June 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (7) , 2736-2744
Preoperative Upper Endoscopy and Surgical Specimen Findings in Bariatric Surgery Patients
Background: The role of routine esophagogastroduodenoscopy (EGD) before metabolic bariatric surgery (MBS) remains unclear. We examined which patients were more likely to undergo preoperative EGD with biopsies, assessed the prevalence of clinically significant gastric pathologies on surgical specimens that may have been missed preoperatively, and analyzed patient factors associated with those findings. Methods: Patients ≥ 18 years old with Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) between 2018 and 2022 were included. Demographic, clinical, endoscopic, and pathology (from EGD and surgical specimens) characteristics were collected. Descriptive statistics were used. Uni- and multivariable Cox regression analyses assessed factors associated with clinically significant endoscopic and pathology findings. Results: Of 3718 patients (38.8% RYGB, 61.2% SG), 80% were female, 69.9% White, and 12.6% Hispanic. Median age at surgery was 45.7 years; median body mass index was 44.5 kg/m2. Preoperative EGD was performed in 36.9% of patients. Surgical specimens were available for 2349 patients (2273 SG and 76 RYGB), among whom 135 had clinically significant pathology. 63.7% of these patients had no preoperative EGD, 15.6% had preoperative EGD without biopsies, and 20.7% preoperative EGD with biopsies. Older age and non-White, non-Black race were associated with clinically significant findings on EGD or pathology. Conclusions: Several clinically relevant gastric pathologies could have been detected preoperatively via EGD with biopsies, yet about two-thirds did not undergo this evaluation. Older age and non-White, non-Black race were associated with these findings. Further research is needed to assess predictive factors of significant findings and cost-effectiveness of routine versus selective pre-operative EGD.
- 5 June 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (7) , 2736-2744
Open AccessPreoperative Upper Endoscopy and Surgical Specimen Findings in Bariatric Surgery Patients
Background: The role of routine esophagogastroduodenoscopy (EGD) before metabolic bariatric surgery (MBS) remains unclear. We examined which patients were more likely to undergo preoperative EGD with biopsies, assessed the prevalence of clinically significant gastric pathologies on surgical specimens that may have been missed preoperatively, and analyzed patient factors associated with those findings. Methods: Patients ≥ 18 years old with Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) between 2018 and 2022 were included. Demographic, clinical, endoscopic, and pathology (from EGD and surgical specimens) characteristics were collected. Descriptive statistics were used. Uni- and multivariable Cox regression analyses assessed factors associated with clinically significant endoscopic and pathology findings. Results: Of 3718 patients (38.8% RYGB, 61.2% SG), 80% were female, 69.9% White, and 12.6% Hispanic. Median age at surgery was 45.7 years; median body mass index was 44.5 kg/m2. Preoperative EGD was performed in 36.9% of patients. Surgical specimens were available for 2349 patients (2273 SG and 76 RYGB), among whom 135 had clinically significant pathology. 63.7% of these patients had no preoperative EGD, 15.6% had preoperative EGD without biopsies, and 20.7% preoperative EGD with biopsies. Older age and non-White, non-Black race were associated with clinically significant findings on EGD or pathology. Conclusions: Several clinically relevant gastric pathologies could have been detected preoperatively via EGD with biopsies, yet about two-thirds did not undergo this evaluation. Older age and non-White, non-Black race were associated with these findings. Further research is needed to assess predictive factors of significant findings and cost-effectiveness of routine versus selective pre-operative EGD.
- Open Access
- 7 May 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (6) , 2191-2201
Indications and Outcomes of Laparoscopic Versus Robotic Conversional Bariatric Surgery: An MBSAQIP Study
Background: Conversional bariatric surgeries (CBS) are performed using laparoscopic and robotic techniques, but comprehensive data comparing these approaches remains scarce. Objective: To compare the indications and outcomes of laparoscopic versus robotic CBS. Methods: The MBSAQIP database was retrospectively analyzed from 2020 to 2022, comparing laparoscopic and robotic CBS. Primary outcomes were 30-day serious complications and mortality. Results: Of 72,189 CBS procedures, 75.4% were laparoscopic and 24.6% robotic. Mean age and BMI were similar between groups. The most common indications for both approaches were reflux, weight regain, and inadequate weight loss, with reflux being more prevalent in robotic CBS (38.3% vs 33.2%). Sleeve-to-bypass was the most common procedure in both groups (35.8% laparoscopic, 44.2% robotic). Robotic CBS had longer mean operative times (165.4 vs 121.7 min, p < 0.001) and slightly longer hospital stays (1.7 vs 1.6 days, p < 0.001). The rate of serious complications was slightly higher for robotic CBS, though not statistically significant (6.5% vs 6.1%, p = 0.08). Robotic CBS had higher rates of leak (0.9% vs 0.7%, p = 0.071), reoperation (2.8% vs 2.6%, p = 0.138), and readmission (6.7% vs 5.4%, p < 0.001). Mortality rates were similar (0.1% for both, p = 0.942). Conclusions: Both laparoscopic and robotic CBS show similar safety profiles with comparable mortality rates. However, robotic CBS was associated with longer operative times, slightly longer hospital stays, and higher readmission rates. These findings suggest that the choice between approaches should consider individual patient factors and institutional expertise.
- 7 May 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (6) , 2191-2201
Open AccessIndications and Outcomes of Laparoscopic Versus Robotic Conversional Bariatric Surgery: An MBSAQIP Study
Background: Conversional bariatric surgeries (CBS) are performed using laparoscopic and robotic techniques, but comprehensive data comparing these approaches remains scarce. Objective: To compare the indications and outcomes of laparoscopic versus robotic CBS. Methods: The MBSAQIP database was retrospectively analyzed from 2020 to 2022, comparing laparoscopic and robotic CBS. Primary outcomes were 30-day serious complications and mortality. Results: Of 72,189 CBS procedures, 75.4% were laparoscopic and 24.6% robotic. Mean age and BMI were similar between groups. The most common indications for both approaches were reflux, weight regain, and inadequate weight loss, with reflux being more prevalent in robotic CBS (38.3% vs 33.2%). Sleeve-to-bypass was the most common procedure in both groups (35.8% laparoscopic, 44.2% robotic). Robotic CBS had longer mean operative times (165.4 vs 121.7 min, p < 0.001) and slightly longer hospital stays (1.7 vs 1.6 days, p < 0.001). The rate of serious complications was slightly higher for robotic CBS, though not statistically significant (6.5% vs 6.1%, p = 0.08). Robotic CBS had higher rates of leak (0.9% vs 0.7%, p = 0.071), reoperation (2.8% vs 2.6%, p = 0.138), and readmission (6.7% vs 5.4%, p < 0.001). Mortality rates were similar (0.1% for both, p = 0.942). Conclusions: Both laparoscopic and robotic CBS show similar safety profiles with comparable mortality rates. However, robotic CBS was associated with longer operative times, slightly longer hospital stays, and higher readmission rates. These findings suggest that the choice between approaches should consider individual patient factors and institutional expertise.
- Open Access
- 10 January 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (2) , 424
Perioperative Outcomes in Patients with and Without Chronic Preoperative Therapeutic Anticoagulation Undergoing Metabolic Surgery at an Academic Medical Center
Background/Objectives: Patients on chronic anticoagulation undergoing metabolic surgery represent an increased risk of complications, including both bleeding and thrombotic events, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). The optimal perioperative management of patients who are receiving chronic anticoagulation therapy (CAT) is complex. In the colorectal surgery literature, patients on CAT have a 10% rate of peri-procedural bleeding and a 3% rate of thromboembolism. The aim of this study was to evaluate and compare the safety and postoperative outcomes between patients with and without CAT undergoing Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) at a tertiary referral center in the United Arab Emirates (UAE). Methods: All patients who underwent primary bariatric surgery between September 2015 and July 2019 were retrospectively reviewed. The first group included patients with CAT, and the second group included patients without CAT. Demographics, perioperative outcomes, and postoperative results were examined. Results: Our study included 542 patients, 22 (4%) with CAT and 520 (96%) without CAT. Mean age was 46.3 ± 10.5 years in the CAT group and 36.0 ± 11.7 years in the non-CAT group (p < 0.001); median BMI was 41.8 (range 33.1–61.3) and 42.7 (range 30.1–78.4) kg/m2, respectively (p = 0.52). The CAT group had significantly higher rates of hypertension (77.2% vs. 32.5%, p < 0.001), obstructive sleep apnea (81.8% vs. 31.5%, p < 0.001), and coronary artery disease (31.8% vs. 2.8%, p < 0.001). In the CAT group, 8/22 (36.4%) patients underwent Roux-en-Y gastric bypass and 14/22 (63.6%) sleeve gastrectomy, compared to 228/520 (43.8%) and 292/520 (56.2%), respectively, in the non-CAT group (p = 0.51). There were no statistically significant differences in postoperative emergency department (ED) visits (18.1% vs. 24.2%, p = 0.51), early major complications (4.5% vs. 3.4%, p = 0.54), readmission rates within 30 days (4.5% vs. 3.6%, p = 0.56), or late complications (4.5% vs. 4.2%, p = 0.60). Mean length of stay was significantly longer in the CAT group (4.6 vs. 2.6 days, p < 0.001). The mean follow-up was 10 ± 7.3 months for the CAT cohort and 11 ± 9.7 months for the non-CAT cohort (p = 0.22). Weight loss outcomes at 12 months were comparable, with a percent total body weight loss (TBWL) of 27.0 ± 7.3% in the CAT group and 28.9 ± 8.3% in the non-CAT group (p = 0.29). There were no deaths in either group. Conclusions: In this series, at a tertiary referral center in the UAE, metabolic surgery is safe for CAT patients. Multidisciplinary preoperative preparation might be warranted to avert potential complications.
- 10 January 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (2) , 424
Open AccessPerioperative Outcomes in Patients with and Without Chronic Preoperative Therapeutic Anticoagulation Undergoing Metabolic Surgery at an Academic Medical Center
Background/Objectives: Patients on chronic anticoagulation undergoing metabolic surgery represent an increased risk of complications, including both bleeding and thrombotic events, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). The optimal perioperative management of patients who are receiving chronic anticoagulation therapy (CAT) is complex. In the colorectal surgery literature, patients on CAT have a 10% rate of peri-procedural bleeding and a 3% rate of thromboembolism. The aim of this study was to evaluate and compare the safety and postoperative outcomes between patients with and without CAT undergoing Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) at a tertiary referral center in the United Arab Emirates (UAE). Methods: All patients who underwent primary bariatric surgery between September 2015 and July 2019 were retrospectively reviewed. The first group included patients with CAT, and the second group included patients without CAT. Demographics, perioperative outcomes, and postoperative results were examined. Results: Our study included 542 patients, 22 (4%) with CAT and 520 (96%) without CAT. Mean age was 46.3 ± 10.5 years in the CAT group and 36.0 ± 11.7 years in the non-CAT group (p < 0.001); median BMI was 41.8 (range 33.1–61.3) and 42.7 (range 30.1–78.4) kg/m2, respectively (p = 0.52). The CAT group had significantly higher rates of hypertension (77.2% vs. 32.5%, p < 0.001), obstructive sleep apnea (81.8% vs. 31.5%, p < 0.001), and coronary artery disease (31.8% vs. 2.8%, p < 0.001). In the CAT group, 8/22 (36.4%) patients underwent Roux-en-Y gastric bypass and 14/22 (63.6%) sleeve gastrectomy, compared to 228/520 (43.8%) and 292/520 (56.2%), respectively, in the non-CAT group (p = 0.51). There were no statistically significant differences in postoperative emergency department (ED) visits (18.1% vs. 24.2%, p = 0.51), early major complications (4.5% vs. 3.4%, p = 0.54), readmission rates within 30 days (4.5% vs. 3.6%, p = 0.56), or late complications (4.5% vs. 4.2%, p = 0.60). Mean length of stay was significantly longer in the CAT group (4.6 vs. 2.6 days, p < 0.001). The mean follow-up was 10 ± 7.3 months for the CAT cohort and 11 ± 9.7 months for the non-CAT cohort (p = 0.22). Weight loss outcomes at 12 months were comparable, with a percent total body weight loss (TBWL) of 27.0 ± 7.3% in the CAT group and 28.9 ± 8.3% in the non-CAT group (p = 0.29). There were no deaths in either group. Conclusions: In this series, at a tertiary referral center in the UAE, metabolic surgery is safe for CAT patients. Multidisciplinary preoperative preparation might be warranted to avert potential complications.
- 27 December 2024
- Published by Springer Nature
- p. 299-307
Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy (SADI-S): Indications and Techniques
- 27 December 2024
- Published by Springer Nature
- p. 299-307
Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy (SADI-S): Indications and Techniques